2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153010
    ER proteostasis regulator-1 912777-95-8 ≥98.0%
    ER proteostasis regulator-1 (compound 481) is a potent ER proteostasis regulator. ER proteostasis regulator-1 has the potential for the research of Alzheimer's disease and diabetes.
    ER proteostasis regulator-1
  • HY-153011
    ROCK-IN-5 692870-25-0 ≥98.0%
    ROCK-IN-5 (compound I-B-37) is a potent inhibitor of ROCK, ERK, GSK, and AGC protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research.
    ROCK-IN-5
  • HY-153058
    LRRK2-IN-8 2770269-44-6 98%
    LRRK2-IN-8 is a LRRK2 inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC50s lower than 10 nM, and inhibits TYK2 and NUAK1 with IC50s of 10-100 nM.
    LRRK2-IN-8
  • HY-153127
    Florbenazine 937245-42-6 98%
    Florbenazine (AV-133) is a diagnostic imaging agent targeting the central nervous system monoamine transporter VMAT2, and its F-18 labeled form can be used for PET scanning. The biodistribution of [18F]Florbenazine in mice shows a high striatum/cerebellum ratio (0.48), which can be used for the diagnostic research of neurodegenerative diseases (including dementia with Lewy bodies and Parkinson's disease).
    Florbenazine
  • HY-153183
    Lp-PLA2-IN-12 2637485-14-2 98%
    Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis.
    Lp-PLA2-IN-12
  • HY-153189
    TrkB-IN-1 1609067-49-3 98%
    TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. TrkB-IN-1 reverses the cognitive defects in an AD mouse model and can be used for alzheimer’s disease research.
    TrkB-IN-1
  • HY-153255
    BACE1-IN-13 1397683-26-9 98%
    BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC50 value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC50 = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models.
    BACE1-IN-13
  • HY-153277
    Axl/Mer/CSF1R-IN-2 2394874-63-4 98%
    Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor.
    Axl/Mer/CSF1R-IN-2
  • HY-153279
    5-LOX-IN-3 1875061-47-4 98%
    5-LOX-IN-3 (Compound 14) is a 5-Lipoxygenase inhibitor (IC50: <1 μM). 5-LOX-IN-3 can be used for research of inflammatory diseases, cancer, stroke and Alzheimer's disease.
    5-LOX-IN-3
  • HY-153427
    Tau protein aggregation-IN-1 916179-45-8 98%
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies.
    Tau protein aggregation-IN-1
  • HY-153430
    Aβ/tau aggregation-IN-3 1210750-32-5 99.70%
    Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC50 of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity.
    Aβ/tau aggregation-IN-3
  • HY-153431
    TRV-1387 1569645-63-1 98%
    TRV-1387 is a benzofurazan that inhibits the aggregation of tau and amyloid-β.
    TRV-1387
  • HY-153432
    TRV-7019 2598164-15-7 99.64%
    TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity.
    TRV-7019
  • HY-15344A
    (S,S)-Ketone monoester 1251829-99-8 98%
    (S,S)-Ketone monoester is a (S,S)-enantiomer of Ketone monoester (HY-15344). Ketone monoester elevates the AcAc and acetone levels, thereby produces sustained ketosis and significantly delays central nervous system oxygen toxicity (CNS-OT) seizures.
    (S,S)-Ketone monoester
  • HY-153458
    Orexin receptor modulator-1 2125735-57-9 98%
    Orexin receptor modulator-1 is an orexin receptor modulator. Orexin receptor modulator-1 can be used for the research of substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Orexin receptor modulator-1
  • HY-153472
    VMAT2-IN-2 tosylate 2608770-12-1 98%
    VMAT2-IN-2 tosylate is a potent VMAT2 inhibitor. VMAT2-IN-2 tosylate can be used in research of tardive dyskinesia.
    VMAT2-IN-2 tosylate
  • HY-153528
    DMAA 73671-86-0 98%
    DMAA is an indirect sympathomimetic amine. DMAA constricts blood vessels and raises blood pressure. DMAA can be used for neurological and cardiovascular disease research.
    DMAA
  • HY-153548
    P2X2/3 modulator-1 1217483-98-1 98%
    P2X2/3 modulator-1 (Compound 46) is a P2X2/3 modulator. P2X2/3 modulator-1 can be used in the study of pain, central nervous system disorders and inflammation.
    P2X2/3 modulator-1
  • HY-153560
    Lp-PLA2-IN-14 2756855-66-8 98%
    Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC50 of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like.
    Lp-PLA2-IN-14
  • HY-153561
    Lp-PLA2-IN-15 1865796-11-7 98%
    Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc.
    Lp-PLA2-IN-15
Cat. No. Product Name / Synonyms Application Reactivity